Navigation Links
Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease
Date:12/24/2013

Among patients with familial amyloid polyneuropathy, a lethal, genetic neurodegenerative disease, use of the nonsteroidal anti-inflammatory agent diflunisal compared with placebo for 2 years reduced the rate of progression in neurological impairment and preserved quality of life, according to a study appearing in the December 25 issue of JAMA.

Familial amyloid polyneuropathy is characterized by progressive neurologic deficits and disability which prove fatal if left untreated. Fewer than 10,000 people are estimated to be clinically affected worldwide, according to background information in the article. Diflunisal showed potential benefit in a phase 1 study.

John L. Berk, M.D., of the Boston University School of Medicine, and colleagues, pursuing the NIH mission to repurpose old drugs, randomized 130 patients from Sweden, Italy, Japan, England, and the United States to receive diflunisal (n=64) or placebo (n=66) twice daily for 2 years to determine the effect of diflunisal on polyneuropathy progression in patients with familial amyloid polyneuropathy.

Patients randomized to diflunisal exhibited less progression of polyneuropathy than those assigned to placebo. The inhibitory effect of diflunisal on neuropathy progression was detectable at 1 and 2 years, and at 2 years, 29.7 percent of the diflunisal group compared to 9.4 percent of the placebo group exhibited neurological stability. Physical quality of life stabilized from the beginning of the study to 2 years in those assigned to diflunisal treatment while decreasing in the placebo group.

The authors write that their trial is pivotal for several reasons: it is the first randomized trial involving a broad cross-section of the spectrum of disease; it provides invaluable natural history data on the rate of neurological disease progression; and it establishes that diflunisal, a low-cost treatment, is well tolerated by familial amyloid polyneuropathy patients with a spectrum of neuropathy.

"Although longer-term follow-up studies are needed, these findings suggest benefit of this treatment for familial amyloid polyneuropathy."


'/>"/>

Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
2. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
3. New anti-inflammatory drugs pinch off reactive oxygen species at the source
4. NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths
5. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
6. Do non-steroidal anti-inflammatory drugs cause kidney failure in children?
7. Revitol Rosacea Now Comes with Anti-Inflammatory Ingredients to Remove Redness and Flushing
8. Revitol Rosacea Now Comes with Anti-Inflammatory Ingredients to Remove Redness and Flushing
9. Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke
10. Birds appear to lack important anti-inflammatory protein
11. Research shows genetic anti-inflammatory defect predisposes children to lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: